open access

Vol 10, No 5 (2021)
Editorial
Published online: 2021-11-03
Get Citation

Gliptin Evidence to fight SARS-CoV-2 Infection

Francesco Ferrara1, Antonio Vitiello1
DOI: 10.5603/DK.2021.0050
·
Clinical Diabetology 2021;10(5):383-385.
Affiliations
  1. USL Umbria 1, Via A. Migliorati 6, 06132 Perugia, Italy

open access

Vol 10, No 5 (2021)
COVID-19 AND DIABETES
Published online: 2021-11-03

Abstract

People with diabetes represent a population at greater risk of infection and complications from SARS-CoV-2. Diabetes represents one of the most important comorbidities related to the severity of viral infection causing an increased risk of serious complications such as severe acute respiratory syndrome and multi-organ dysfunction associated with a hyperinflammatory state. Glycemic normalization in patients with diabetes must be managed in the best possible way even during SARS-CoV-2 infection to avoid serious complications. However, for some antidiabetic agents such as DPP-4 inhibitors (gliptins) there is evidence of efficacy against SARS-CoV-2 extra pancreatic glycemic normalization. The objective of this article is to provide an overview of current evidence on the potential therapeutic benefits of gliptins to combat SARS-CoV-2 infection.

Abstract

People with diabetes represent a population at greater risk of infection and complications from SARS-CoV-2. Diabetes represents one of the most important comorbidities related to the severity of viral infection causing an increased risk of serious complications such as severe acute respiratory syndrome and multi-organ dysfunction associated with a hyperinflammatory state. Glycemic normalization in patients with diabetes must be managed in the best possible way even during SARS-CoV-2 infection to avoid serious complications. However, for some antidiabetic agents such as DPP-4 inhibitors (gliptins) there is evidence of efficacy against SARS-CoV-2 extra pancreatic glycemic normalization. The objective of this article is to provide an overview of current evidence on the potential therapeutic benefits of gliptins to combat SARS-CoV-2 infection.

Get Citation

Keywords

gliptins, diabetes, SARS-CoV-2, infection, virology.

About this article
Title

Gliptin Evidence to fight SARS-CoV-2 Infection

Journal

Clinical Diabetology

Issue

Vol 10, No 5 (2021)

Article type

Editorial

Pages

383-385

Published online

2021-11-03

DOI

10.5603/DK.2021.0050

Bibliographic record

Clinical Diabetology 2021;10(5):383-385.

Keywords

gliptins
diabetes
SARS-CoV-2
infection
virology.

Authors

Francesco Ferrara
Antonio Vitiello

References (25)
  1. World Health Organization HO (2020) Coronavirus disease 2019 (COVID-19) situation report. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
  2. Vitiello A, Ferrara F, Pelliccia C, et al. Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia. Italian Journal of Medicine. 2020; 14(2): 88–94.
  3. Lin L, Lu L, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020; 9(1): 727–732.
  4. Ferrara F, Granata G, Pelliccia C, et al. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020; 76(11): 1615–1618.
  5. Vitiello A, Ferrara F. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know? Eur J Pharmacol. 2020; 883: 173373.
  6. Zou Q, Zheng S, Wang X, et al. Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments. Int J Infect Dis. 2020; 92: 208–213.
  7. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? The Lancet. 2020; 395(10231): 1225–1228.
  8. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19 Lancet Diabetes Endocrinol. Lancet Diabetes Endocrinol. 2020(8): 546–550.
  9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–280.e8.
  10. Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol. 2009; 302(2): 193–202.
  11. Yang JK, Lin SS, Ji XJ, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010; 47(3): 193–199.
  12. Vitiello A, Ferrara F. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2021; 156: 105579.
  13. Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020; 262: 118510.
  14. Ferrara F. Anti-rheumatic in SARS-CoV-2: benefit or risk? Italian Journal of Medicine. 2020.
  15. Ferrara F, Porta RLa, D'Aiuto V, et al. Remdesivir and COVID-19. Ir J Med Sci. 2020 [Epub ahead of print].
  16. Vitiello A, Ferrara F, Porta RLa. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021 [Epub ahead of print].
  17. Vitiello A, Ferrara F. Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2020 [Epub ahead of print].
  18. Ferrara F, Porta RLa, Santilli P, et al. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol. 2020; 52(5): 441–442.
  19. Raj V, Mou H, Smits S, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495(7440): 251–254.
  20. Li K, Wohlford-Lenane CL, Channappanavar R, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A. 2017; 114(15): E3119–E3128.
  21. Fan C, Wu Xi, Liu Q, et al. A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. Viruses. 2018; 10(9).
  22. Yang W, Cai X, Han X, et al. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2016; 32(4): 391–404.
  23. Raj V, Mou H, Smits S, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013; 495(7440): 251–254.
  24. Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020; 162: 108125.
  25. Klonoff DC. The Coronavirus 2019 Pandemic and Diabetes: An International Perspective. J Diabetes Sci Technol. 2020; 14(4): 703–704.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl